11/21/2024
5:30 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
5:30 PM | Fairmount Funds Management LLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13D/A | |
11/14/2024
6:38 PM | Avidity Partners Management LP (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
4:49 PM | Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
4:20 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
11/14/2024
3:56 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
11:04 AM | Allostery Investments LP (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G/A | |
|
11/14/2024
8:56 AM | JANUS HENDERSON GROUP PLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
5:37 AM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
11/13/2024
3:01 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/22/2024
3:15 PM | Adage Capital Management, L.P. (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13D/A | |
10/18/2024
3:11 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form DEF 14A | |
10/07/2024
10:37 AM | FMR LLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G | |
10/04/2024
3:05 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/13/2024
3:55 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/13/2024
3:57 PM | Fairmount Funds Management LLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13D/A | |
09/06/2024
4:00 PM | Klein Lawrence Otto (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:01 PM | Agarwal Arjun (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:02 PM | Goncalves Joana (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:03 PM | Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Quinlan Paul T (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:04 PM | BALL KRISTINE M (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:05 PM | Dambkowski Carl (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:06 PM | Kulkarni Samarth (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:07 PM | Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Turtle Cameron (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:07 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Co-Invest III L.P. (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:08 PM | Fairmount Funds Management LLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13D | |
09/05/2024
4:18 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/30/2024
4:57 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Ma-Weaver Jacob (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/26/2024
6:51 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/26/2024
6:53 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
08/23/2024
3:35 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/20/2024
1:23 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Janus Henderson Biotech Innovation Master Fund Ltd (Reporting)
JANUS HENDERSON GROUP PLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/16/2024
3:25 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/16/2024
3:27 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
08/15/2024
3:15 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/15/2024
3:17 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
08/09/2024
7:35 AM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
08/01/2024
3:30 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
07/26/2024
9:50 AM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Janus Henderson Biotech Innovation Master Fund Ltd (Reporting)
JANUS HENDERSON GROUP PLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/24/2024
11:15 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form EFFECT | |
07/24/2024
3:49 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form ARS | |
When it comes to NVDA… “acceleration cycles” are the key (Ad) Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options…
By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)...
And thanks to many months and late nights working out the kinks of the systems…
They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! |
07/22/2024
4:17 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-4/A | |
07/12/2024
6:38 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Janus Henderson Biotech Innovation Master Fund Ltd (Reporting)
JANUS HENDERSON GROUP PLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
6:10 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Janus Henderson Biotech Innovation Master Fund Ltd (Reporting)
JANUS HENDERSON GROUP PLC (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
07/09/2024
4:29 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-4/A | |
07/09/2024
4:01 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/09/2024
4:04 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
07/05/2024
4:20 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
06/18/2024
4:17 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-4/A | |
06/06/2024
3:45 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
05/13/2024
8:11 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-4
Registration statement under Securities Act of 1933 | |
04/29/2024
6:28 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G | |
04/25/2024
3:27 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
04/23/2024
3:20 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/15/2024
4:29 PM | Allostery Investments LP (Filed by)
ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G | |
04/11/2024
8:51 AM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G | |
04/09/2024
7:57 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
Avidity Partners Management LP (Filed by)
| Form SC 13G | |
04/05/2024
6:38 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
Western Standard LLC (Filed by)
| Form SC 13G/A | |
04/03/2024
6:31 AM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/03/2024
6:33 AM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
02/07/2024
12:08 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
BML Investment Partners, L.P. (Filed by)
| Form SC 13G/A | |
02/01/2024
3:39 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/31/2024
5:39 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Ma-Weaver Jacob (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Woosley Raymond L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Grais Linda (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
CONWAY ROBERT E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Flynn James P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
MITCHELL DANIEL J (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Hove Anders D (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/05/2023
3:25 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/04/2023
3:36 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
